Physician profile
Robert Samuel Eagerton
NPI 1558366039
$5,446.32
in general payments reported to CMS, 2019-2025
40 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $707 · 2021: $796 · 2022: $472 · 2023: $730 · 2024: $956 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $995.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $526.80 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $475.73 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $366.25 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $350.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $257.69 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Sanofi-Aventis U.S. LLC | $247.66 | 2019-2022 | |
| Lilly USA, LLC | $213.57 | 2020-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.32 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $185.31 | 2021-2024 | Xarelto |
| Supernus Pharmaceuticals, INC. | $144.30 | 2019-2020 | |
| Abbott Laboratories | $139.39 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $126.08 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.13 | 2023-2025 | Xifaxan |
| Amarin Pharma, INC. | $109.78 | 2020-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $107.33 | 2020-2021 | |
| Exact Sciences Corporation | $104.84 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $87.35 | 2021-2024 | |
| Mylan Specialty L.P. | $69.71 | 2020-2022 | |
| Dexcom, INC. | $66.65 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $57.40 | 2021 | |
| Corcept Therapeutics | $47.67 | 2025 | Korlym |
| Neuraxis, INC. | $47.31 | 2024 | |
| Renalytix Ai, INC. | $43.81 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.42 | 2025 | Caplyta |
| Medicure Pharma INC. | $32.82 | 2021 | |
| Edwards Lifesciences Corporation | $32.65 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Axsome Therapeutics, INC. | $28.42 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $26.90 | 2025 | Trelegy Ellipta |
| Verity Pharmaceuticals INC. | $24.33 | 2024 | Tlando |
| Phathom Pharmaceuticals, INC. | $22.15 | 2024-2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $20.28 | 2024 | Strensiq |
| Astellas Pharma US INC | $20.14 | 2023 | Veozah |
| Azurity Pharmaceuticals, INC. | $18.41 | 2024 | |
| Intra-Sana Laboratories | $18.13 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Actelion Pharmaceuticals US, INC. | $17.12 | 2024 | Opsumit, Uptravi |
| Ironshore Pharmaceuticals INC. | $16.38 | 2019 | |
| Tactile Systems Technology INC | $16.06 | 2025 | Nimbl, Flexitouch Plus |
| Daiichi Sankyo INC. | $15.21 | 2025 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $14.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Eagerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.